Article Information
History
- July 31, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Aganze Gloire-Aimé Mushebenge1,2,3,*,
- Samuel Chima Ugbaja3,
- Nonkululeko Avril Mbatha4,
- Manimani Ghislain Riziki5,
- Tambwe Willy Muzumbukilwa1,
- Mukanda Gedeon kadima1,
- Manimbulu Nlooto6 and
- Hezekiel M. Kumalo3
- 1Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Westville-Durban, South Africa
- 2Centre in Indigenous Knowledge Systems-DSI/NRF, University of KwaZulu-Natal, South Africa, Westville-Durban, South Africa
- 3Drug Research and Innovation Unit, Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa;
- 4Africa Health Research Institute, University of KwaZulu-Natal, Durban 4000, South Africa;
- 5Department of Internal Medicine, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa;
- 6Pharmacy Department, School of Health Care Sciences, Faculty of Health University of Limpopo, South Africa
- ↵*Corresponding author: Aganze Gloire-Aimé Mushebenge, Email: aganzedar{at}Gmail.com, alternative E-mail: Kumaloh{at}ukzn.ac.za
Posted July 31, 2023.
An updated research focus on the employment of computer-aided drug discovery and repurposing techniques for the identification and evaluation of SARS-CoV-2 Main protease inhibitors: A protocol for a systematic review and meta-analysis
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos